S'abonner

Therapeutic potential of Angelica sinensis in addressing organ fibrosis: A comprehensive review - 22/03/24

Doi : 10.1016/j.biopha.2024.116429 
Xiaodong Zhi a, b, c, d, 1, Chunzhen Ren a, b, c, 1, Qianrong Li a, b, c, Huaqing Xi a, b, c, Dong Li f, Qilin Chen a, b, c, Xinfang Lv a, b, c, d, Xiang Gao a, b, c, d, Xue Wu a, b, c, e, Chunling Wang a, b, c, d, Bing Jiang a, b, c, Zhongnan Mao d, Hugang Jiang a, b, c, Kai Liu a, b, c, Xinke Zhao a, b, c, d, , Yingdong Li a, b, c,
a School of Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, China 
b Gansu Province Key Laboratory of Chinese Medicine for the Prevention and Treatment of Chronic Diseases, Lanzhou 730000, China 
c Key clinical specialty of the National Health Commission of the People’s Republic of China, Key Specialized Cardiovascular Laboratory National Administration of Traditional Chinese Medicine, Lanzhou 730000, China 
d Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou 730000, China 
e The second hospital of Lanzhou University, Lanzhou 730000, China 
f Qingyang Hospital of Traditional Chinese Medicine, Qingyang 745000, China 

Corresponding author at: Affiliated Hospital of Gansu University of Chinese Medicine, Lanzhou 730000, China.Affiliated Hospital of Gansu University of Chinese MedicineLanzhou730000China⁎⁎Correspondence to: School of Traditional Chinese and Western Medicine, Gansu University of Chinese Medicine, Dingxi Road, Lanzhou 730000, China.School of Traditional Chinese and Western Medicine, Gansu University of Chinese MedicineDingxi RoadLanzhou730000China

Abstract

Fibrosis-related diseases (FRD) include conditions like myocardial fibrosis, pulmonary fibrosis, hepatic fibrosis, renal fibrosis, and others. The impact of fibrosis can be severe, causing organ dysfunction, reduced functionality, and even organ failure, leading to significant health issues. Currently, there is a lack of effective modern anti-fibrosis drugs in clinical practice. However, Chinese medicine has a certain beneficial effect on the treatment of such diseases. Angelica sinensis, with its considerable medicinal value, has garnered attention for its anti-fibrosis properties in recent investigations. In the past few years, there has been a growing number of experimental inquiries into the impact of angelica polysaccharide (ASP), angelica water extract, angelica injection, and angelica compound preparation on fibrosis-associated ailments, piquing the interest of researchers. This paper aims to consolidate recent advances in the study of Angelica sinensis for the treatment of fibrosis-related disorders, offering insights for prospective investigations. Literature retrieval included core electronic databases, including Baidu Literature, CNKI, Google-Scholar, PubMed, and Web of Science. The applied search utilized specified keywords to extract relevant information on the pharmacological and phytochemical attributes of plants. The investigation revealed that Angelica sinensis has the potential to impede the advancement of fibrotic diseases by modulating inflammation, oxidative stress, immune responses, and metabolism. ASP, Angelica sinensis extract, Angelica sinensis injection, and Angelica sinensis compound preparation were extensively examined and discussed. These constituents demonstrated significant anti-fibrosis activity. In essence, this review seeks to gain a profound understanding of the role of Angelica sinensis in treating fiber-related diseases. Organ fibrosis manifests in nearly all tissues and organs, posing a critical challenge to global public health due to its widespread occurrence, challenging early diagnosis, and unfavorable prognosis. Despite its prevalence, therapeutic options are limited, and their efficacy is constrained. Over the past few years, numerous studies have explored the protective effects of traditional Chinese medicine on organ fibrosis, with Angelica sinensis standing out as a multifunctional natural remedy. This paper provides a review of organ fibrosis pathogenesis and summarizes the recent two decades’ progress in treating fibrosis in various organs such as the liver, lung, kidney, and heart. The review highlights the modulation of relevant signaling pathways through multiple targets and channels by the effective components of Angelica sinensis, whether used as a single medicine or in compound prescriptions.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




Le texte complet de cet article est disponible en PDF.

Keywords : Angelica sinensis, Organ fibrosis, Hepatic fibrosis, Pulmonary fibrosis, Renal fibrosis, Myocardial fibrosis, Myofibroblast


Plan


© 2024  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 173

Article 116429- avril 2024 Retour au numéro
Article précédent Article précédent
  • Emerging role of N6-methyladenosine RNA modification in regulation of SARS-CoV-2 infection and virus-host interactions
  • Jiayi Liu, Lingli Chen, Xiongmin Guo, Bingrong Zhao, Juan Jiang
| Article suivant Article suivant
  • Painful diabetic neuropathy: The role of ion channels
  • Qi Wang, Yifei Ye, Linghui Yang, Lifan Xiao, Jin Liu, Wensheng Zhang, Guizhi Du

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.